[1] Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med, 2004, 350(19): 1937-1944.
[2] Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med, 2004, 350(19): 1945-1952.
[3] Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochemistry(Mosc), 2008, 73(5): 605-618.
[4] Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003, 3(5): 330-338.
[5] Spalding AC, Lawrence TS. New and emerging radiosensitizers and radioprotectors. Cancer Invest, 2006, 24(4): 444-456.
[6] Morgan MA, Parsels LA, Maybaum J, et al. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res, 2008, 14(21): 6744-6750.
[7] Morgan MA, Parsels LA, Parsels JD, et al. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemci-tabine. Cancer Res, 2005, 65(15): 6835-6842.
[8] Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother, 2005, 6(1): 85-92.
[9] Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs, 2007, 67(14): 2045-2075.
[10] Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. Nat Rev Clin Oncol, 2010, 7(7): 401-414.
[11] Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs, 2010, 19(9): 1049-1066.
[12] Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat(PRAVO)phase 1 study. Lancet Oncol, 2010, 11(5): 459-464.
[13] Shabason JE, Tofilon PJ, Camphausen K. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. J Cell Mol Med, 2011, 15(12): 2735-2744.
[14] Chen X, Wong P, Radany EH, et al. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res, 2012, 10(8): 1052-1064.
[15] Kim KW, Mutter RW, Cao C, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther, 2006, 5(11): 2659-2665.
[16] Johnson GE, Ivanov VN, Hei TK. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis, 2008, 13(6): 790-802.
[17] Chen J, Wang J, Lin L, et al. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Mol Cancer Ther, 2012, 11(2): 277-287.
[18] Löser DA, Shibata A, Shibata AK, et al. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose)polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther, 2010, 9(6): 1775-1787.
[19] Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434(7035): 917-921.
[20] Chalmers AJ, Lakshman M, Chan N, et al. Poly(ADP-ribose)polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol, 2010, 20(4): 274-281.
[21] Che SM, Zhang XZ, Hou L, et al. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest, 2010, 28(7): 679-688.
[22] Che SM, Zhang XZ, Liu XL, et al. The radiosensitization effect of NS398 on esophageal cancer stem cell—like radioresistant cells. Dis Esophagus, 2011, 24(4): 265-273.
[23] Dittmann KH, Mayer C, Ohneseit PA, et al. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys, 2008, 70(1): 203-212.
[24] Grimes KR, Warren GW, Fang F, et al. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep, 2006, 16(4): 771-776.
[25] Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation, 2008, 117(16): 2104-2113.
[26] Cerella C, Sobolewski C, Dicato M, et al. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem Pharmacol, 2010, 80(12): 1801-1815.
[27] Härdtner C, Multhoff G, Falk W, et al. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol, 2012, 684(1-3): 36-43.
[28] Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal, 2005, 7(11-12): 1630-1647.
[29] Nambiar D, Rajamani P, Singh RP. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res, 2011, 728(3): 139-157.
[30] Qiao Q, Jiang Y, Li G. Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-κB pathway: an in-vitro study of lymphoma. Anticancer Drugs, 2012, 23(6): 597-605.
[31] Veeraraghavan J, Natarajan M, Lagisetty P, et al. Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells. Pancreas, 2011, 40(7): 1107-1119.
[32] Liu J, Zhang J, Wang X, et al. HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res, 2010, 316(12): 1985-1993.
[33] Moon SY, Chang HW, Roh JL, et al. Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral oncol, 2009, 45(10): 915-919.
[34] Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer, 2009, 100(5): 747-757.
[35] Lee K, Zhang H, Qian DZ, et al. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA, 2009, 106(42): 17910-17915.
[36] Kim WY, Oh SH, Woo JK, et al. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res, 2009, 69(4): 1624-1632.
[37] Semenza GL. Hypoxia-inducible factor 1(HIF-1)pathway. Sci STKE, 2007, 2007(407): cm8.
[38] Singh-Gupta V, Zhang H, Banerjee S, et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer, 2009, 124(7): 1675-1684.
[39] Shi M, Guo XT, Shu MG, et al. Cell-permeable hypoxia-inducible factor-1(HIF-1)antagonists function as tumor radiosensitizers. Med Hypotheses, 2007, 69(1): 33-35.
[40] Yang CM, Lee IT, Lin CC, et al. Cigarette smoke extract induces COX-2 expression via a PKCalpha/c-Src/EGFR, PDGFR/PI3K/Akt/NF-kappaB pathway and p300 in tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2009, 297(5): L892-902.
[41] Cheng JC, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene, 2006, 25(53): 7009-7018.
[42] Rudner J, Ruiner CE, Handrick R, et al. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol, 2010, 5: 108.
[43] Kao GD, Jiang Z, Fernandes AM, et al. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J Biol Chem, 2007, 282(29): 21206-21212.
[44] Chendil D, Ranga RS, Meigooni D, et al. Curcumin confers radio-sensitizing effect in prostate cancer cell line PC-3. Oncogene, 2004, 23(8): 1599-1607.
[45] Sandur SK, Deorukhkar A, Pandey MK, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys, 2009, 75(2): 534-542.
[46] Sung B, Pandey MK, Ahn KS, et al. Anacardic acid(6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappa Balpha kinase, leading to potentiation of apoptosis. Blood, 2008, 111(10): 4880-4891.
[47] Zand H, Rahimipour A, Salimi S, et al. Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression. Mol Cell Biochem, 2008, 317(1-2): 113-120.
[48] Wang L, Fu JN, Wang JY, et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anticancer Drugs, 2011, 22(8): 732-740.
[49] Taba K, Kuramitsu Y, Ryozawa S, et al. KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy, 2011, 57(1): 12-16.
[50] Sahin E, Sahin M, Sanliolu AD, et al. KNK437, a benzylidene lactam compound, sensitises prostate cancer cells to the apoptotic effect of hyperthermia. Int J Hyperthermia, 2011, 27(1): 63-73.
[51] Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res, 2004, 64(24): 9152-9159.
[52] Won J, Kim M, Kim N, et al. Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol, 2006, 2(7): 369-374.
[53] Rainey MD, Charlton ME, Stanton RV, et al. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res, 2008, 68(18): 7466-7474.
[54] Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev, 2009, 109(7): 2974-2988.
[55] 王浩, 周晓靓, 施培基, 等.靶向放射增敏剂的研究进展.中华放射医学与防护杂志, 2011, 31(2): 243-245.